RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced the opening of a new European training and research and development center in Milan, Italy. The facility, to be called the TransEnterix Milan Robotic Surgery Center, was inaugurated on December 15, 2016 in a special ceremony. It is part of the technology and research village next to the University Milano-Bicocca campus.
“The Senhance Surgical Robot has strong development roots in the innovation corridor found in Lombardy and Italy,” said Todd M. Pope, President and CEO at TransEnterix. “We are pleased to make this investment to create a world-class center for robotic surgical training and to continue our research and development in Milan, which will bring surgeons and researchers from across the globe together to help create the next wave of robotic surgery.”
The new robotic center will feature an integrated demonstration operating theater, robotic training and development systems, and facilities for hosting large groups. It will also serve as the Company’s European research and development facility that will further enable research collaborations with the European Union’s Joint Research Center, academic institutions and industry partners across Europe.
A number of surgeons that have pioneered the clinical use of this new system for robotic surgery and senior executives from TransEnterix were present, along with representatives of healthcare industry associations and government. The event was hosted at the new TransEnterix Milan Robotic Surgery Center, and following remarks by the special guests, participants were able to experience the Senhance Surgical System and tour the facility.
TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the commercialization of the Senhance™ Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The company is also developing the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System has been granted a CE Mark but is not currently available for sale in the United States. For more information, visit the TransEnterix website at www.transenterix.com.
Forward Looking Statements
This press release includes statements relating to the Senhance™ Surgical Robotic System and our current regulatory and commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether our European training and research development center in Milan, Italy will be a world-class center for robotic training and research and development. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 3, 2016 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.